Multiple Sclerosis, Secondary Progressive Clinical Trial
Official title:
The Effects of In-phase Bilateral Exercise on Cognitive and Motor Outcome Measures, in Patients With Progressive Multiple Sclerosis, a Randomized Control Trial.
Verified date | May 2024 |
Source | Cyprus University of Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. MS, typical presents with progression of clinical symptoms which mainly include motor and cognitive impairment, as well as reduction of patients' quality of life. Exercise is an effective approach in the management of the symptoms in people with progressive MS. Previous studies in healthy and in people with MS, reported a close relationship between cognitive functions and upper limb performance. Since patients with progressive MS facing difficulties with performing complex exercises due to cognitive dysfunctions and given the close relationship between cognitive functions and manual dexterity, a reasonable question arises whether a type of upper limbs exercises with less cognitive demands will improve the information processing speed in people with progressive MS. The aim of the current study is to investigate the effects of in-phase bilateral upper limbs exercises on the information processing speed, in patients with progressive MS, given that in-phase bilateral movements needs less attentional load than the other types of bilateral coordination. The intervention protocol lasted for 12 consecutive weeks (30-60 minutes /session x 3 sessions/week) and included in-phase bilateral exercises of the upper limbs, adapted to different sports activities and to functional training. Results from the statistical analysis indicated improvement of the experimental group compared to the control group, on the information processing speed alongside with improvement of motor skills.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 22, 2023 |
Est. primary completion date | December 22, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 70 Years |
Eligibility | Inclusion Criteria: - diagnosis of progressive multiple sclerosis (MS) (primary or/and secondary progressive MS) - Expanded Disability Status Scale score between three and six - no relapse within 30 days - aged between 30 and 70 years - Mini Mental State of Examination score between 20 and 30 (mild to no cognitive impairment) Exclusion Criteria: - history of any disease affecting the central nervous system other than MS (e.g., stroke, Parkinson's disease, cerebral palsy) - history of cardiovascular disease (e.g., known aneurism, myocardial infarction, hyper/hypotension, heart failure) - severe orthopaedic disorders (e.g., knee or hip replacement, spondylosurgery, disk herniation, recent bone fracture) - mental disorders (e.g., depression, schizophrenia, bipolar syndrome) - pregnancy during the implementation of the study timeline - hearing impairments (i.e., deafness) - visual deficit (e.g., optic neuritis, blindness, diplopia, glaucoma, blurred vision) - history of epileptic seizures - spasticity level on upper or lower limbs more than 1+ (slight increase in muscle tone) according to Modified Ashworth Scale |
Country | Name | City | State |
---|---|---|---|
Cyprus | Dimitris Sokratous | Limassol |
Lead Sponsor | Collaborator |
---|---|
Cyprus University of Technology | Cyprus Institute of Neurology and Genetics |
Cyprus,
Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000 Jun;4(6):215-222. doi: 10.1016/s1364-6613(00)01483-2. — View Citation
DeLuca J, Chiaravalloti ND, Sandroff BM. Treatment and management of cognitive dysfunction in patients with multiple sclerosis. Nat Rev Neurol. 2020 Jun;16(6):319-332. doi: 10.1038/s41582-020-0355-1. Epub 2020 May 5. — View Citation
Grefkes C, Eickhoff SB, Nowak DA, Dafotakis M, Fink GR. Dynamic intra- and interhemispheric interactions during unilateral and bilateral hand movements assessed with fMRI and DCM. Neuroimage. 2008 Jul 15;41(4):1382-94. doi: 10.1016/j.neuroimage.2008.03.048. Epub 2008 Apr 8. — View Citation
Paus T. Primate anterior cingulate cortex: where motor control, drive and cognition interface. Nat Rev Neurosci. 2001 Jun;2(6):417-24. doi: 10.1038/35077500. — View Citation
Sokratous D, Charalambous CC, Papanicolaou EZ, Michailidou K, Konstantinou N. Investigation of in-phase bilateral exercise effects on corticospinal plasticity in relapsing remitting multiple sclerosis: A registered report single-case concurrent multiple baseline design across five subjects. PLoS One. 2023 Mar 2;18(3):e0272114. doi: 10.1371/journal.pone.0272114. eCollection 2023. — View Citation
Swinnen SP, Wenderoth N. Two hands, one brain: cognitive neuroscience of bimanual skill. Trends Cogn Sci. 2004 Jan;8(1):18-25. doi: 10.1016/j.tics.2003.10.017. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Symbol Digit Modalities Test | It is a commonly used test in pwMS, which measures processing speed as well as motor speed. The investigators employed the oral form of the test, in which participants were provided with the test sheet with nine symbols, each paired with a number on top of the page, defined as the "key". For example, the symbol "O" is matched with the number "6", so the correct response would be "six". The rest of the page consists of a randomized, sequential variety of these symbols. Participants are asked to verbally respond with the number that corresponds with each symbol. During the test, the participant is given two minutes to orally match symbols with digits as quickly as possible. The score is obtained by subtracting the number of errors from the number of items completed. To account for practice effects, the investigators created six different tests, as many as our assessment points, in which the order of the symbols and the numbers of the "key" were rearranged | Baseline (3 weeks) until the end of the Intervention (12 weeks) | |
Secondary | Medical Outcomes Study Short Form 36 | It is a set of generic, coherent, and easily administered quality-of-life measures, completed by the participants. There are 11 questions in the specific questionnaire administered by an assessor, with 36 items in total, which cover eight domains scaled from 0 to 100, with higher values indicating better health status. The eight domains include: general health, vitality, physical function, role physical, bodily pain, role emotional, social functioning and mental health. It takes between 5 and 10 min to complete it. | Baseline (3rd week) until the end of the Intervention (12 weeks) | |
Secondary | Modified Fatigue Impact Scale | It is a short questionnaire which requires the participants to describe the effects of fatigue during the past four weeks. The Modified Fatigue Impact Scale consists of 21 questions which are subjectively rated from "0" (low rate) to "4" (high rate) and it is divided into three subscales (i.e., physical, cognitive, and psychosocial). The assessor records the total score of the test as the final test result. The higher the score is, the greater is the impact of fatigue in individual daily life. Therefore, the Modified Fatigue Impact Scale it is used as the description of participants' attribution of functional restrictions to fatigue symptoms. | Baseline (3rd week) until the end of the Intervention (12 weeks) | |
Secondary | Trail Making Test | It contains five conditions; the visual scanning, motor speed, number sequencing, letter sequencing, and number-letter switching. Trail Making Test also assesses attention, information processing speed and mental flexibility. This particular test consists of two parts, A and B, which involves 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the participant should connect the numbers in ascending order by drawing lines. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the participants connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (e.g., 1-A-2-B-3-C, etc.). The participants were instructed to connect the circles as quickly as possible, without lifting the pencil from the paper. During participants' connection of the "trails", the assessor notes possible errors, and the time needed to complete the task. | Baseline (3 weeks) until the end of the Intervention (12 weeks) | |
Secondary | Purdue Pegboard Test | It is a standardized test of manual dexterity. The Purdue Pegboard Test consists of four subtests, performed in a board in which pins, washers and collars are placed by the participants into two parallel columns of holes, according to the subtest task. The first two subtests are unimanual tasks, which measure dexterity of the right and left hand, respectively. The third subtest is a synchronous bimanual task that requires simultaneous use of both hands to grasp pins and place them in their corresponding columns of holes. During the fourth subtest, the participants should perform alternating movements of both hands to complete assemblies of different types of pegs. Standard scoring of the Purdue Pegboard Test is based on the number of pegs inserted in 30 s for the first three subtests, and in 1 min for the last subtest. | Baseline (3 weeks) until the end of the Intervention (12 weeks) | |
Secondary | Timed 25-Foot Walk | It is a quantitative assessment for mobility and lower limb function. Participants are directed to one end of a marked 25-foot path and they are instructed to walk as quickly as possible. The time is recorded from the start and ended when participants reached the 25-foot mark. The same task is immediately run again by having the participants walked back the same distance. Due to the fact that our participants might be using assistive devices for walking, they are instructed to use them in order to be safe when doing this task. The final score for each participant, is the mean score from the two completed trials. | Baseline (3 weeks) until the end of the Intervention (12 weeks) | |
Secondary | Six Spot Step Test | It is a measure replicating a complex range of sensorimotor functions, such as lower limb strength, spasticity, coordination, as well as balance. It is a timed walking test that involves kicking over a number of targets placed along a 5 meter path. The specific test is cognitive demanding, that also includes coordination and dynamic balance. | Baseline (3 weeks) until the end of the Intervention (12 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT02273635 -
Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS
|
Phase 1/Phase 2 | |
Recruiting |
NCT05961644 -
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
|
Phase 2/Phase 3 | |
Recruiting |
NCT05013463 -
Hydroxychloroquine and Indapamide in SPMS
|
Phase 2 | |
Recruiting |
NCT04918225 -
Motor Asymmetry in Progressive Multiple Sclerosis Patients
|
||
Completed |
NCT01982942 -
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
|
Phase 2 | |
Recruiting |
NCT05204459 -
MS-ResearchBiomarkerS
|
||
Terminated |
NCT02430532 -
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS)
|
Phase 3 | |
Completed |
NCT00888277 -
Bayer/Cognitive Assessments With Multiple Sclerosis Subjects
|
N/A | |
Completed |
NCT05663853 -
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
|
||
Recruiting |
NCT05168384 -
Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02305264 -
Imaging of Intracerebral Inflammation in MS
|
N/A | |
Terminated |
NCT00468611 -
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
|
Phase 3 | |
Recruiting |
NCT05496881 -
Exercise Effects in Multiple Sclerosis
|
N/A | |
Completed |
NCT05357833 -
Novel Imaging Markers in SPMS
|
Early Phase 1 | |
Not yet recruiting |
NCT06390930 -
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
|
N/A | |
Completed |
NCT02506751 -
Open-label Study of Liothyronine in MS
|
Phase 1 | |
Completed |
NCT00587691 -
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04260711 -
Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
|
N/A | |
Completed |
NCT02308137 -
Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)
|
Phase 2 |